» Articles » PMID: 2181374

Strong Association Between C-myb and Oestrogen-receptor Expression in Human Breast Cancer

Overview
Journal Oncogene
Date 1990 Jan 1
PMID 2181374
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Previous articles have reported that the c-myb proto-oncogene was activated in various types of tumours of the hematopoietic system suggesting that this gene plays a role in the development of these malignancies. However no studies of the c-myb gene have as yet been performed in solid primary tumours. In the present study we have analysed in breast cancer the c-myb gene with the aim to determine its involvement in tumour progression. Expression of the c-myb oncogene was analysed from 169 carcinoma specimens obtained from untreated patients with non-inflammatory breast cancer (NBC) (112 patients) and inflammatory breast cancer (IBC) (57 patients). A 3.5 kb c-myb transcript band was detected in 108 (64%) tumours. c-myb expression was found to be associated with good prognostic factors (lowest histopathologic grade (P = 0.01), oestrogen and progesterone receptor status (P less than 10(-4)) and pS2 gene expression (P less than 10(-4)) and negatively correlated with breast cancers of poorer prognosis, namely IBC (P = 0.03) and NBC with multiple involved nodes (P = 0.15). Other genes (c-myc, c-erbB2, c-fos and epidermal growth factor receptor) were also studied. The c-myb gene expression was found to be inversely correlated (P less than 0.03) with only c-erbB2 overexpression in NBC. When data were analysed with a logistic regression model using a stepwise procedure, c-myb expression was found to be associated only with the oestrogen receptor status (P less than 10(-4)). In conclusion, our data indicate that analysis of c-myb expression in breast cancer could allow the characterization of a new class of oestrogen-dependent tumours.

Citing Articles

Transcription Factor MYB as Therapeutic Target: Current Developments.

Klempnauer K Int J Mol Sci. 2024; 25(6).

PMID: 38542205 PMC: 10970396. DOI: 10.3390/ijms25063231.


Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities.

Kohler L, Reich S, Yusenko M, Klempnauer K, Begemann G, Schobert R Cancer Drug Resist. 2023; 6(1):59-77.

PMID: 37065868 PMC: 10099595. DOI: 10.20517/cdr.2022.90.


RNF6 activates TGF-β1/c-Myb pathway to promote EMT in esophageal squamous cell carcinoma.

Cheng J, Wu K, Yang Q, Zhu Z, Zhao H Front Oncol. 2023; 13:1081333.

PMID: 36845743 PMC: 9948393. DOI: 10.3389/fonc.2023.1081333.


Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity.

Yusenko M, Biyanee A, Frank D, Kohler L, Andersson M, Khandanpour C Cancers (Basel). 2022; 14(1).

PMID: 35008207 PMC: 8750090. DOI: 10.3390/cancers14010043.


Molecular Mechanisms of Antiproliferative and Apoptosis Activity by 1,5-Bis(4-Hydroxy-3-Methoxyphenyl)1,4-Pentadiene-3-one (MS13) on Human Non-Small Cell Lung Cancer Cells.

Wan Mohd Tajuddin W, Abas F, Othman I, Naidu R Int J Mol Sci. 2021; 22(14).

PMID: 34299042 PMC: 8307969. DOI: 10.3390/ijms22147424.